Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients

被引：0
|
作者：
Nunes, D. [1 ]
Dansin, E. [2 ]
Lamblin, C. [3 ]
Wasielewski, E. [1 ]
Descarpentries, C. [4 ]
Gregoire, V. [4 ]
Copin, M. C. [4 ]
Escande, F. [4 ]
Cortot, A. [1 ]
机构：
[1] Lille Univ Hosp, Thorac Oncol, Lille, France
[2] Ctr Oscar Lambret, Lille, France
[3] Clin La Louviere, Lille, France
[4] Ctr Biol & Pathol, Lille, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
T790M; Rebiopsies; EGFR;
D O I：
10.1016/j.jtho.2017.09.1531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-002
引用
收藏
页码：S2237 / S2238
页数：2
相关论文
共 50 条
  • [1] Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
    Kuiper, J. L.
    Heideman, D. A. M.
    Thunnissen, E.
    Paul, M. A.
    van Wijk, A. W.
    Postmus, P. E.
    Smit, E. F.
    [J]. LUNG CANCER, 2014, 85 (01) : 19 - 24
  • [2] Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    Wu, Yi-Long
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1341 - 1342
  • [3] Osimertinib in EGFR-Mutated Advanced NSCLC
    Staege, Martin S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1863 - +
  • [4] Gefitinib Approved for EGFR-Mutated NSCLC
    不详
    [J]. CANCER DISCOVERY, 2015, 5 (09) : 896 - 896
  • [5] Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases
    Zhang, Jinyao
    Wang, Yan
    Liu, Ziling
    Wang, Lin
    Yao, Yu
    Liu, Yutao
    Hao, Xue Zhi
    Wang, Jianyang
    Xing, Puyuan
    Li, Junling
    [J]. THORACIC CANCER, 2021, 12 (24) : 3407 - 3415
  • [6] Clinical analysis of the presence of comutations in patients with EGFR-mutated NSCLC
    Rubio, Jaime
    Santolaya, Carlota
    Fernandez, Marina
    Villalba, Paula Lucia
    Avedillo, Mercedes
    Garcia-Foncillas, Jesus
    Domine, Manuel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] EGFR-mutated NSCLC: A roadmap to treatment sequences
    Girard, Nicolas
    [J]. MED, 2024, 5 (09): : 1044 - 1047
  • [8] Resistance landscape to almonertinib in EGFR-mutated NSCLC
    Tian, M.
    Lu, Z.
    Chen, S.
    Lu, G.
    Bu, F.
    Deng, W.
    Ding, R.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1017 - S1017
  • [9] Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC
    Steendam, C.
    Van Schaik, R.
    Oomen-De Hoop, E.
    Atmodimedjo, P.
    De Jonge, E.
    Von der Thusen, J.
    Dinjens, W.
    Dubbink, E. J.
    Aerts, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S809 - S809
  • [10] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
12345